Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2022

View Archived Issues

Medshine Discovery identifies new CREBBP and/or p300 inhibitors

Shionogi discovers 5-HT2A receptor antagonists and/or inverse agonists

New galectin-3 inhibitors synthesized at Galecto Biotech

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents G12C mutant GTPase KRAS inhibitors

IDP Discovery Pharma describes new VEGF inhibitors

M2-mAChRs as therapeutic targets for treating substance use disorders

Discovery of a new class of PDE4B inhibitors with activity in adjuvant-induced arthritis model

RAP-103 studies show potential of biphasic function opioid signaling modulators for use in analgesia

Step Pharma's CTPS1 inhibitor STP-938 cleared to enter clinic for T-cell and B-cell lymphomas

Tonix and KEMRI collaborate to advance TNX-801 as vaccine for monkeypox and smallpox

Neuron-like cells are glioblastoma's evil mastermind

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...